Randomized, Placebo-controlled Trial of Injectable Naltrexone and Monthly Injectable Buprenorphine for Methamphetamine Use Disorder (MURB)

The 4th wave of the opioid crisis involves increasing polydrug stimulant and opiate use. Incidence of overdose deaths due to polysubstance use involving opioids co-occurring with methamphetamine increased from 2017 to 2018 by 14.6%. According to the National Survey on Drug Use and Health in 2018, an estimated 1,867,000 of persons in US aged 12 years and older, reported methamphetamine use in the past year and 1,051 000 reported substance use disorder in the past year involving methamphetamines. There are no effective medications for treating methamphetamine use disorder. This proposal will test the superiority of long-acting buprenorphine (and its kappa antagonist activity) over placebo as a treatment for methamphetamine use disorder among persons who co-use opioids.

CTN Protocol ID: 
CTN-0110
Status: 
Development

Principal Investigator(s)

Steve Shoptaw, Ph.D.

Professor and Vice Chair for Research Department of Family Medicine
University of California, Los Angeles

10880 Wilshire Boulevard, Suite 1800
Los Angeles, CA 90024
United States

Madhukar H. Trivedi, M.D.

Betty Jo Hay Distinguished Chair in Mental Health Professor, Node Principal Investigator
University of Texas Southwestern Medical Center
Department of Psychiatry

5323 Harry Hines Boulevard
Dallas, TX 75390
United States